Author

Sara Bravaccini

Istituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriORCID 0000-0002-0075-8538Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Abdullah AltuleaiD· 1 shared Abel Soto-GameziD· 1 shared Boshi WangiD· 1 shared Caterina GianniiD· 1 shared Jamil NehmeiD· 1 shared Marco DemariaiD· 1 shared Michele ZanoniiD· 1 shared Sjors MaasseniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdullah AltuleaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacological CDK4/6 inhibitors promote senescence-associated lysosomal alterations and enhance sensitivity to lysosomotropic agents in breast cancer

Jamil Nehme, Sjors Maassen, Sara Bravaccini, Michele Zanoni, Caterina Gianni, Ugo De Giorgi, Abel Soto-Gamez, Abdullah Altulea, Teodora Gheorghe, Boshi Wang, Marco Demaria

This study shows CDK4/6 inhibitors induce senescence-like changes in breast cancer cells, increasing their sensitivity to lysosomotropic agents, and suggests sequential treatment could improve therapy efficacy.

The EMBO Journal · Feb 10, 2025Peer-reviewedCancer Biology